{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:21:21Z","timestamp":1765354881810},"reference-count":63,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"paper was developed with assistance from a professional medical writer"},{"name":"Global Blood Therapeutics Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2022,6,3]]},"DOI":"10.1080\/17474086.2022.2082408","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T16:01:25Z","timestamp":1654617685000},"page":"485-492","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Voxelotor for the treatment of sickle cell disease in pediatric patients"],"prefix":"10.1080","volume":"15","author":[{"given":"Clark","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Emory School of Medicine, Aflac Cancer and Blood Disorder Center of Children\u2019s Healthcare of Atlanta, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Tonda","sequence":"additional","affiliation":[{"name":"Global Blood Therapeutics, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel R.","family":"Abboud","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.10"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30193-9"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89741"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61229-X"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0348"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.152"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.08.021103"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2011.09.013"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.09.001"},{"key":"cit0010","unstructured":"US Food and Drug Administration. Sickle cell disease 2022 [cited 2022 Mar 11]. Available from: https:\/\/www.fda.gov\/consumers\/minority-health-and-health-equity\/sickle-cell-disease-fact-sheet"},{"key":"cit0011","unstructured":"Centers for Disease Control and Prevention. Data and statistics on sickle cell disease 2022 [cited 2022 Mar 31]. Available from: https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.2.776.bloodjournal862776"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24796"},{"issue":"1","key":"cit0014","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21550","volume":"85","author":"Ballas SK","year":"2010","journal-title":"Am J Hematol"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24855"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22242"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.3014"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13525"},{"issue":"1","key":"cit0019","first-page":"288","volume":"91","author":"Ohene-Frempong K","year":"1998","journal-title":"Blood"},{"key":"cit0020","first-page":"303","volume":"74","author":"Mehta SR","year":"2006","journal-title":"Am Fam Physician"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390102"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12950"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2020.08.009"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.07.826"},{"key":"cit0025","unstructured":"US Department of Health and Human Services. Sickle Cell Disease 2020 [cited 2022 Mar 31]. Available from: https:\/\/www.hhs.gov\/cto\/initiatives\/digital-services\/health-plus\/sickle-cell-disease\/index.html"},{"key":"cit0026","unstructured":"Wilson-Frederick S, Hulihan M, Anderson K Prevalence of sickle cell disease among Medicaid beneficiaries in 2012. US Department of Health and Human Services; 2019 [cited 2022 Mar 31]. Available from: https:\/\/www.cms.gov\/About-CMS\/Agency-Information\/OMH\/research-and-data\/information-products\/data-highlights\/Prevalence-of-Sickle-Cell-Disease-among-Medicaid-Beneficiaries-in-2012"},{"key":"cit0027","unstructured":"Valentine A, Ayo-Vaughan M, Faborode O, et al. Advancing care for sickle cell disease: a strategic roadmap. 2021 [cited 2021 Nov 3]. Available from: https:\/\/sickcells.org\/wp-content\/uploads\/2021\/01\/20210119-Sick-Cells-Strategic-Roadmap-for-Advancing-SCD-Care-FINAL-1.pdf"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28006"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22433.1"},{"key":"cit0030","unstructured":"US Food and Drug Administration. FDA approves hydroxyurea for treatment of pediatric patients with sickle cell anemia [Internet]. Silver Spring, MD: US Food and Drug Administration; 2017 Dec 21 [cited 2022 Dec 21]. Available from: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm590096.htm"},{"key":"cit0031","first-page":"1","volume-title":"Expert panel report, 2014","author":"National Heart Lung and Blood Institute","year":"2014"},{"key":"cit0032","unstructured":"Emmaus Medical Inc. Oral-L-glutamine powder for the treatment of sickle cell disease. Emmaus Medical Inc. 2017 [cited 2022 Mar 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208587s000lbl.pdf"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"cit0034","volume-title":"Prescribing information","author":"Oxbryta","year":"2021"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-019-1225-7"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000282"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117175"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-02138-w"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00059-4"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1893688"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118508"},{"key":"cit0043","unstructured":"European Commission approves Oxbryta\u00ae (voxelotor) for the treatment of hemolytic anemia in patients with sickle cell disease age 12 years and older [Internet]. Global Blood Therapeutics, Inc.; 2022 Feb 16 [cited 2022 Feb 17]. Available from: https:\/\/ir.gbt.com\/news-releases\/news-release-details\/european-commission-approves-oxbrytar-voxelotor-treatment"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868893"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14214"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.3233\/CH-170340"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.435"},{"issue":"1","key":"cit0048","first-page":"509","volume":"132","author":"Clark B","year":"2018","journal-title":"Blood"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29716"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012070"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00048.2021"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2031967"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18076"},{"key":"cit0054","unstructured":"Study to evaluate the effect of GBT440 on TCD in pediatrics with sickle cell disease (HOPE Kids 2): clinicalTrials.gov Identifier: NCT04218084; [updated 2021 Dec 22; cited 2022 Dec 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04218084"},{"key":"cit0055","unstructured":"Expanded access protocol for pediatric patients with sickle cell disease who have no alternative treatment options: ClinicalTrials.gov Identifier: NCT04724421; [updated 2021 Dec 29; cited 2022 Feb 14]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04724421"},{"key":"cit0056","unstructured":"Retrospective Real World Oxbryta\u00ae Data Collection and Analysis Study (RETRO): ClinicalTrials.gov Identifier: NCT04930328; [updated 2021 Oct 22; cited 2022 Feb 14]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04930328"},{"key":"cit0057","unstructured":"Phase 3b, randomized, double-blind, placebo-controlled, multicenter study to evaluate the treatment effect of voxelotor on neurocognitive function in pediatric participants 8 to < 18 years of age with sickle cell disease: clinicalTrials.gov Identifier: NCT05228834; 2022 [updated 2022 Feb 8; cited 2022 Mar 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05228834"},{"key":"cit0058","volume-title":"Presented at FSCDR\u2019s Inaugural Nursing in Sickle Cell Disease Symposium: Advancing the Science of Sickle Cell Disease","author":"Brown C"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13782"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-002215"},{"key":"cit0061","unstructured":"Study to evaluate the effect of GBT440 in pediatrics with sickle cell disease (HOPE kids). ClinicalTrials.gov Identifier: NCT02850406 2022 [cited 2022 Feb 8]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02850406"},{"key":"cit0062","unstructured":"Study to evaluate the effect of voxelotor administered orally to patients with sickle cell disease (GBT HOPE). ClinicalTrial.gov Identifier: NCT03036813 2021 [cited 2021 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03036813"},{"issue":"1","key":"cit0063","volume":"134","author":"Ware RE","year":"2019","journal-title":"Blood"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2022.2082408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T19:52:27Z","timestamp":1700682747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2022.2082408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,3]]}},"alternative-id":["10.1080\/17474086.2022.2082408"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2022.2082408","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}